SOM Biotech collaborated in the organization of the University of Barcelona Summer Course: "Rare Diseases: from the patient to the cure". Within the framework of the course, Dr. Raúl Insa, SOM Biotech CEO, did a master class included in the module “Pharmaceuticals in rare diseases”. The topic of his speech was: "Repositioning of drugs in…

Oscar Huertas, Drug Discovery Manager, and Maria Zimina, Business Development Manager of SOM Biotech, participated at DIT Barcelona Biotech Breakfast: Applying AI in Drug Discovery and Development. The event took place at the Parc Cientific de Barcelona on 19th of June 2019. The event included masterclasses in an open panel discussion format with leading British and Catalan speakers…

Dr. Raúl Insa, SOM Biotech CEO, participated in the Clinical Roundtable at Veeva R&D Summit Europe 2019.  The clinical team of SOM Biotech: Dr. Santiago Esteva and Aileen Ferré, attended the conference sessions organized in the framework of the Summit. The Summit took place in Barcelona last 11-13 June 2019. Veeva R&D Summit Europe is…

SOM Biotech attended the BIO International Convention in Philadelphia last 3-6 June 2019. BIO is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on major trends affecting the industry. This year 4.075 companies attended with more than…

Dr. Raúl Insa, SOM Biotech CEO, gave a talk on the topic "Repositioning of Utrophin" at the International Congress 2019 on Duchenne Muscular Dystrophy and Becker, an event organized by Duchenne Parent Project España. The Congress took place in Madrid from 7th to 9th of June. The Congress analyzed the different therapeutic strategies that exist…

Dr. Raúl Insa, SOM Biotech CEO, gave an interview to Labiotech.eu, leading digital media covering the European Biotech industry, read by 100000+ monthly visitors. In this interview, Dr. Insa explained the mission of SOM Biotech, advantages of drug repurposing and aspects of drug development for Orphan diseases. SOM Biotech’s CEO also talked about the current…